Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?

Thomas Eiwegger, Katherine Anagnostou, Stefania Arasi, Philippe Bégin, Moshe Ben-Shoshan, Kirsten Beyer, Katharina Blumchen, Helen Brough, Jean Christoph Caubet, Edmond S. Chan, Meng Chen, Sharon Chinthrajah, Carla M. Davis, Anne Des Roches, George Du Toit, Arnon Elizur, Stephen J. Galli, Geir Håland, Karin Hoffmann-Sommergruber, Harold KimDonald Y.M. Leung, Andrew Long, Antonella Muraro, Ulugbek B. Nurmatov, Giovanni B. Pajno, Vanitha Sampath, Jamie Saxena, Sayantani Sindher, Julia Upton, Margitta Worm, Kari C. Nadeau*

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Editorial

13 Citations (Scopus)
Original languageEnglish
Pages (from-to)1153-1156
Number of pages4
JournalJournal of Allergy and Clinical Immunology
Issue number4
Publication statusPublished - Apr 2020
Externally publishedYes


  • efficacy
  • Food allergy
  • Institute for Clinical and Economic Review
  • management
  • peanut allergy
  • quality of life
  • safety
  • treatment
  • US Food and Drug Administration Allergenic Products Advisory Committee
  • Academies and Institutes
  • Administration, Oral
  • United States
  • Humans
  • Desensitization, Immunologic/methods
  • Advisory Committees
  • Policy Making
  • Government Regulation
  • Peanut Hypersensitivity/immunology
  • United States Food and Drug Administration

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this